Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
Clicks: 261
ID: 267839
2014
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
7.2
/100
24 views
24 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection. (Funded by Gilead Sciences; ION-1 ClinicalTrials.gov number NCT01701401.).
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (29 words).
Try re-searching for a better abstract.
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.